Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocyte differentiation by antagonists of adipogenesis.
3T3-L1 preadipocytes differentiate into cells having the biochemical properties of adipocytes; tumor necrosis factor-alpha (TNF), retinoic acid (RA), and transforming growth factor-beta (TGF-beta), attenuate this process. Inhibition of differentiation by these agents, thought to be at the level of transcription, has been investigated by examining the accumulation of mRNA for six transcription factors and the autocrine growth factor interleukin 6 (IL-6). Upon induction of differentiation, a rapid and major accumulation of c-fos and jun-B mRNA was observed that returned to near basal levels within 4-6 h. In contrast, c-jun mRNA, although rapidly expressed following induction of differentiation, remained at relatively constant levels throughout the time course. Exposure of the cells to 5 nM TNF potentiated the accumulation of all 3 mRNAs but most significantly c-jun (12-fold), which remained elevated for at least 24 h after treatment. In control differentiating cells, krox-20 and fox-B were expressed transiently, 30 min to 2 h, while fra-1 mRNA accumulated over an extended period, 1 to 8 h. Again, TNF enhanced the accumulation of these mRNAs. Accumulation of mRNA for C/EBP, a transcription factor proposed to control expression of genes involved in the terminally differentiated state was attenuated after exposure of the cells to TNF. C/EBP expression was also inhibited in cells exposed to RA or TGF-beta. IL-6 mRNA was expressed briefly (30 min to 2 h) and again transiently (at 8 h after induction of differentiation). TNF treatment markedly enhanced accumulation of IL-6 message.(ABSTRACT TRUNCATED AT 250 WORDS)
Stephens
J M
JM
Department of Biochemistry, School of Medicine, East Carolina University, Greenville, NC 27858.
Butts
M
M
Stone
R
R
Pekala
P H
PH
Bernlohr
D A
DA
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D016475:3T3 Cells; D000199:Actins / Q000235:genetics / Q000378:metabolism; D000273:Adipose Tissue / Q000166:cytology* / Q000378:metabolism; D000818:Animals; D015152:Blotting, Northern; D022762:CCAAT-Enhancer-Binding Proteins; D002454:Cell Differentiation; D004268:DNA-Binding Proteins / Q000235:genetics; D003907:Dexamethasone / Q000494:pharmacology; D005786:Gene Expression Regulation; D051272:Glucose Transporter Type 1; D006801:Humans; D007328:Insulin / Q000494:pharmacology; D015850:Interleukin-6 / Q000235:genetics / Q000378:metabolism; D051379:Mice; D009004:Monosaccharide Transport Proteins / Q000235:genetics / Q000378:metabolism; D009687:Nuclear Proteins / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D014157:Transcription Factors / Q000235:genetics* / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D014212:Tretinoin / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D000199:Actins; D022762:CCAAT-Enhancer-Binding Proteins; D004268:DNA-Binding Proteins; D051272:Glucose Transporter Type 1; D007328:Insulin; D015850:Interleukin-6; D009004:Monosaccharide Transport Proteins; D009687:Nuclear Proteins; D012333:RNA, Messenger; C495677:SLC2A1 protein, human; D014157:Transcription Factors; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D014212:Tretinoin; D003907:Dexamethasone; D015056:1-Methyl-3-isobutylxanthine